Abstract:Identification of regulatable mechanisms by which transcription factor NF-E2 p45-related factor 2 (Nrf2) is repressed will allow strategies to be designed that counter drug resistance associated with its upregulation in tumours that harbour somatic mutations in Kelch-like ECH-associated protein-1 (Keap1) , a gene that encodes a joint adaptor and substrate receptor for the Cul3–Rbx1/Roc1 ubiquitin ligase. We now show that mouse Nrf2 contains two binding sites for β-transducin repeat-containing protein (β-TrCP), which acts as a substrate receptor for the Skp1–Cul1–Rbx1/Roc1 ubiquitin ligase complex. Deletion of either binding site in Nrf2 decreased β-TrCP-mediated ubiquitylation of the transcription factor. The ability of one of the two β-TrCP-binding sites to serve as a degron could be both increased and decreased by manipulation of glycogen synthase kinase-3 (GSK-3) activity. Biotinylated-peptide pull-down assays identified DSGIS 338 and DSAPGS 378 as the two β-TrCP-binding motifs in Nrf2. Significantly, our pull-down assays indicated that β-TrCP binds a phosphorylated version of DSGIS more tightly than its non-phosphorylated counterpart, whereas this was not the case for DSAPGS. These data suggest that DSGIS, but not DSAPGS, contains a functional GSK-3 phosphorylation site. Activation of GSK-3 in Keap1-null mouse embryonic fibroblasts (MEFs), or in human lung A549 cells that contain mutant Keap1 , by inhibition of the phosphoinositide 3-kinase (PI3K)–protein kinase B (PKB)/Akt pathway markedly reduced endogenous Nrf2 protein and decreased to 10–50% of normal the levels of mRNA for prototypic Nrf2-regulated enzymes, including the glutamate-cysteine ligase catalytic and modifier subunits, glutathione S- transferases Alpha-1 and Mu-1, haem oxygenase-1 and NAD(P)H:quinone oxidoreductase-1. Pre-treatment of Keap1 −/− MEFs or A549 cells with the LY294002 PI3K inhibitor or the MK-2206 PKB/Akt inhibitor increased their sensitivity to acrolein, chlorambucil and cisplatin between 1.9-fold and 3.1-fold, and this was substantially attenuated by simultaneous pre-treatment with the GSK-3 inhibitor CT99021.

The Nrf3 Transcription Factor is a Membrane-bound Glycoprotein Targeted to the Endoplasmic Reticulum Through Its N-terminal Homology Box 1 Sequence

The Nhb1 (N-Terminal Homology Box 1) Sequence in Transcription Factor Nrf1 is Required to Anchor It to the Endoplasmic Reticulum and Also to Enable Its Asparagine-Glycosylation

The Nrf1 CNC/bZIP Protein is a Nuclear Envelope-Bound Transcription Factor That is Activated by T-Butyl Hydroquinone but Not by Endoplasmic Reticulum Stressors.

Identification of topological determinants in the N-terminal domain of transcription factor Nrf1 that control its orientation in the endoplasmic reticulum membrane.

Nrf1 is Targeted to the Endoplasmic Reticulum Membrane by an N-terminal Transmembrane Domain INHIBITIONOFNUCLEARTRANSLOCATIONANDTRANSACTINGFUNCTION *

Negative Regulation of the Nrf1 Transcription Factor by Its N-terminal Domain is Independent of Keap1: Nrf1, but Not Nrf2, is Targeted to the Endoplasmic Reticulum

Transcription Factor Nrf1 is Topologically Repartitioned Across Membranes to Enable Target Gene Transactivation Through Its Acidic Glucose-Responsive Domains.

Identification of an Adaptor Protein That Facilitates Nrf2-Keap1 Complex Formation and Modulates Antioxidant Response.

The Selective Post-Translational Processing of Transcription Factor Nrf1 Yields Distinct Isoforms That Dictate Its Ability to Differentially Regulate Gene Expression

The C-Terminal Domain Of Nrf1 Negatively Regulates The Full-Length Cnc-Bzip Factor And Its Shorter Isoform Lcr-F1/Nrf1 Beta; Both Are Also Inhibited By The Small Dominant-Negative Nrf1 Gamma/Delta Isoforms That Down-Regulate Are-Battery Gene Expression

The Membrane-Topogenic Vectorial Behaviour of Nrf1 Controls Its Post-Translational Modification and Transactivation Activity

All-Trans Retinoic Acid Affects Subcellular Localization of A Novel Bmnif3l Protein: Functional Deduce and Tissue Distribution of Nif3l Gene from Silkworm (bombyx Mori)

N-glycosylation of the human neuropeptide QRFP receptor (QRFPR) is essential for ligand binding and receptor activation

Nrf1D is the first candidate secretory transcription factor in the blood plasma, with its precursor existing as a unique redox-sensitive transmembrane CNC-bZIP protein in somatic tissues

Mechanisms controlling the multistage post-translational processing of endogenous Nrf1α/TCF11 proteins to yield distinct isoforms within the coupled positive and negative feedback circuits.

Nrf1D is the First Candidate Secretory Transcription Factor in the Blood Plasma, Its Precursor Existing As a Unique Redox-Sensitive Transmembrane CNC-bZIP Protein in Hemopoietic and Somatic Tissues.

Molecular mechanisms controlling the multistage post-translational processing of endogenous Nrf1α/TCF11 proteins to yield distinct proteoforms within the coupled positive and negative feedback circuits

Topovectorial Mechanisms Control the Juxtamembrane Proteolytic Processing of Nrf1 to Remove Its N-terminal Polypeptides During Maturation of the CNC-bZIP Factor

Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity

Activation of the Membrane-Bound Nrf1 Transcription Factor by USP19, a Ubiquitin-Specific Protease C-terminally Anchored in the Endoplasmic Reticulum

Transcriptional Regulation by Nrf2